checkAd

    EQS-Adhoc  158  0 Kommentare Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir - Seite 3


    End of ad hoc announcement
    Language: English
    Company: RELIEF THERAPEUTICS Holding AG
    Avenue de Sécheron 15
    1202 Genève
    Switzerland
    E-mail: contact@relieftherapeutics.com
    Internet: https://relieftherapeutics.com
    ISIN: CH0100191136
    Listed: SIX Swiss Exchange
    EQS News ID: 1252715

     
    End of Announcement EQS Group News Service

    1252715  29-Nov-2021 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1252715&application_name=news&site_id=wallstreet

    Lesen Sie auch

    Seite 3 von 3




    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-Adhoc Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir - Seite 3 EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Study results Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer